The case for & against
Bull & Bear analysis
Bullish
AUNA (NYSE: AUNA) is a leading healthcare services provider in Latin America, primarily engaged in operating hospitals, health insurance plans, and outpatient services across Mexico, Colombia, and Peru. The company is focused on enhancing healthcare delivery through an integrated model that emphasizes high-complexity services such as oncology and cardiology. As AUNA seeks to navigate a fragmented healthcare landscape, it strategically emphasizes operational efficiencies and market share growth, positioning itself as a significant player in the region's healthcare sector.
Bull says
- ↑Revenue grew 10% YoY to 1.2B soles in Q1 2026.
- ↑Free cash flow jumped 2.6× to 152M soles, bolstering cash reserves.
- ↑Oncology and cardiology volumes rising, driving higher-margin service demand.
- ↑Risk-sharing agreements now >10% of revenues, enhancing cash flow visibility.
- ↑Dividend yield 0.61% and earnings yield 0.32% indicate income/value appeal.
- ↑Low volatility and positive analyst revisions underpin stability outlook.
Bear says
- ↓Negative profitability score highlights persistent margin pressure.
- ↓Adjusted EBITDA fell 5% amid revenue adjustments and payroll increases.
- ↓Weak momentum trends deter investors, reflecting price stagnation.
- ↓13F ownership low, signalling limited institutional interest.
- ↓High-complexity share below 10% in key markets risks growth potential.
- ↓Leverage at 3.7× may stress financials if costs rise further.
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 08-20-2026neutral
Transcript signals
Bull points
- 8% growth was mainly due to total plan member growth, as well as surgery volume growth and price service mix.
- Peru's EBITDA grew 8%. Overall, Peru's margin remained unchanged at a very solid 21%.
- Mexico's adjusted EBITDA margin remained at a healthy 32%.
Bear points
- as we remain focused on risk mitigation and improving our cash conversion cycle there.
- Peru's revenue growth slowed in the quarter, it continued to be a strong top line contributor.
- Free cash flow was $143 million versus $155 million in the first six months of last year, primarily impacted by 19 million soles in payments to the Opción Oncología doctors, as well as collections in the first quarter.
Read full transcript analysis ›